|
|
||||||||
Basic Science Investigation |
1 Ernst Felder Laboratories, Bracco Research USA Inc., Princeton, New Jersey; 2 Bracco Imaging S.p.A., Milan, Italy; and 3 Institute of Pathology, University of Bern, Bern, Switzerland
Correspondence: For correspondence or reprints contact: Laura E. Lantry, PhD, Discovery Biology, Ernst Felder Laboratories, Bracco Research USA Inc., 305 College Rd. East, Princeton, NJ 08540-6608. E-mail: Laura.Lantry{at}bru.bracco.com
Gastrin-releasing peptide receptors (GRP-R) are upregulated in many cancers, including prostate, breast, and lung. We describe a new radiolabeled bombesin (BBN) analog for imaging and systemic radiotherapy that has improved pharmacokinetics (PK) and better retention of radioactivity in the tumor. Methods: DO3A-CH2CO-G-4-aminobenzoyl-Q-W-A-V-G-H-L-M-NH2 (AMBA) was synthesized and radiolabeled. The human prostate cancer cell line PC-3 was used to determine the binding (Kd), retention, and efflux of 177Lu-AMBA. Receptor specificity was determined by in vitro autoradiography in human tissues. PK and radiotherapy studies were performed in PC-3 tumor-bearing male nude mice. Results: 177Lu-AMBA has a high affinity for the GRP-R (Kd, 1.02 nmol/L), with a maximum binding capacity (Bmax) of 414 fmol/106 cells (2.5 x 105 GRP-R/cell). Internalization was similar for 177Lu-AMBA (76.8%), 177Lu-BBN8 (72.9%), and 125I-[Tyr4]-BBN (74.9%). Efflux was markedly lower for 177Lu-AMBA (2.9%) compared with 177Lu-BBN8 (15.9%) and 125I-[Tyr4]-BBN (46.1%). By receptor autoradiography, Lu-AMBA binds specifically to GRP-R (0.8 nmol/L) and to the neuromedin B receptor (NMB-R) (0.9 nmol/L), with no affinity for the bb3 receptor (>1,000 nmol/L). 177Lu-AMBA was renally excreted (55 %ID 1 h [percentage injected dose at 1 h]); tumor uptake at 1 and 24 h was 6.35 %ID/g and 3.39 %ID/g, respectively. One or 2 doses of 177Lu-AMBA (27.75 MBq/dose) significantly prolonged the life span of PC-3 tumor-bearing mice (P < 0.001 and P < 0.0001, respectively) and decreased PC-3 tumor growth rate over controls. When compared using World Health Organization criteria, mice receiving 2 doses versus 1 dose of 177Lu-AMBA demonstrated a shift away from stable/progressive disease toward complete/partial response; by RECIST (Response Evaluation Criteria in Solid Tumors), median survival increased by 36% and time to progression/progression-free survival increased by 65%. Conclusion: 177Lu-AMBA binds with nanomolar affinity to GRP-R and NMB-R, has low retention of radioactivity in kidney, demonstrates a very favorable riskbenefit profile, and is in phase I clinical trials.
Key Words: gastrin-releasing peptide prostate cancer experimental radiotherapeutics 177Lu preclinical
Related articles in JNM:
This article has been cited by other articles:
![]() |
R. T. Jensen, J. F. Battey, E. R. Spindel, and R. V. Benya International Union of Pharmacology. LXVIII. Mammalian Bombesin Receptors: Nomenclature, Distribution, Pharmacology, Signaling, and Functions in Normal and Disease States Pharmacol. Rev., March 1, 2008; 60(1): 1 - 42. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Cescato, T. Maina, B. Nock, A. Nikolopoulou, D. Charalambidis, V. Piccand, and J. C. Reubi Bombesin Receptor Antagonists May Be Preferable to Agonists for Tumor Targeting J. Nucl. Med., February 1, 2008; 49(2): 318 - 326. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Cornelio, R Roesler, and G Schwartsmann Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy Ann. Onc., September 1, 2007; 18(9): 1457 - 1466. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. C. Garrison, T. L. Rold, G. L. Sieckman, S. D. Figueroa, W. A. Volkert, S. S. Jurisson, and T. J. Hoffman In Vivo Evaluation and Small-Animal PET/CT of a Prostate Cancer Mouse Model Using 64Cu Bombesin Analogs: Side-by-Side Comparison of the CB-TE2A and DOTA Chelation Systems J. Nucl. Med., August 1, 2007; 48(8): 1327 - 1337. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |